Vanadium - Medesis Pharma

Drug Profile

Vanadium - Medesis Pharma

Alternative Names: NP-01 - Medesis Pharma

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator Medesis Pharma
  • Class Heavy metals; Transition elements; Vanadium compounds
  • Mechanism of Action Insulin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Metabolic syndrome

Most Recent Events

  • 28 Jun 2016 Phase I development is ongoing in France (Medesis Pharma pipeline, May 2016)
  • 31 May 2010 Medesis Pharma completes a phase I trial in Metabolic syndrome (In volunteers) in France (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top